Related Experiment Videos
Expression of p53 in oligodendrogliomas
J M Kros1, J J Godschalk, K K Krishnadath
1Department of Pathology, University Hospital Rotterdam-Dijkzigt, Erasmus University Rotterdam, The Netherlands.
The Journal of Pathology
|December 1, 1993
Summary
High p53 protein expression in oligodendrogliomas, indicated by over 75% of cells being p53-immunolabeled, predicts a poor clinical outcome. Lower expression does not rule out a rapid fatal course for these brain tumors.
Area of Science:
- Oncology
- Molecular Pathology
- Neurosurgery
Background:
- Oligodendrogliomas are primary brain tumors.
- The p53 tumor suppressor protein plays a critical role in cell cycle regulation and apoptosis.
- Altered p53 expression is implicated in various cancers, including gliomas.
Purpose of the Study:
- To investigate the expression of the nuclear protein p53 in oligodendrogliomas.
- To correlate p53 expression levels with histopathological grade and patient survival.
- To assess changes in p53 expression in tumor recurrences.
Main Methods:
- Immunohistochemistry using a monoclonal anti-p53 antibody (DO-7).
- Analysis of formalin-fixed, paraffin-embedded tissue from 84 oligodendroglioma cases.
- Comparison of p53 labeling index with tumor grade, mitotic index, and ploidy status.
Main Results:
- p53-immunoreactive cells were detected in 75% of initial biopsy samples.
- A p53 labeling index exceeding 75% was associated with a rapidly fatal clinical course.
- No significant correlation was found between p53 labeling index and tumor grade, mitotic index, or ploidy.
- In most recurrences, p53 labeling index increased or remained stable; it was absent in 6% of cases at both biopsy and recurrence.
Conclusions:
- A high percentage (over 75%) of p53-immunolabeled cells in oligodendrogliomas is predictive of an unfavorable clinical course.
- Lower percentages of p53-immunoreactive cells do not exclude a rapid fatal outcome.
- p53 expression patterns may offer prognostic insights in oligodendroglioma management.